MedTrace Logo

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

NCT07293754 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-02-17

No results posted yet for this study

Summary

This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.

Conditions

  • Advanced Malignant Solid Tumor

Interventions

DRUG

RPTR-1-201

RPTR-1-201

DRUG

PD-1 / PD-L1 monoclonal antibody

PD-1/PD-L1 monoclonal antibody

Sponsors & Collaborators

  • Repertoire Immune Medicines

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-12
Primary Completion
2028-12-15
Completion
2029-04-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07293754 on ClinicalTrials.gov